Viraj Master, MD
Urology · Atlanta, GANPI 1982632089
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (59.7%), education and food and beverage — rather than concentrated in one kind of arrangement. 6 manufacturers reported payments, led by Exelixis Inc. at 38.8% of the total.
Across 22 payments — averaging $577.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Exelixis Inc.$5K
- Telix Pharmaceuticals$4K
- Pfizer$3K
- Cook Medical LLC$251
- Boston Scientific$124
- Baxter Healthcare$111
Across 118 payments — averaging $16,514 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$1.4M
- Janssen Research & Development, LLC$159K
- Artivion, Inc.$126K
- E.r. Squibb & Sons, L.L.C.$115K
- QED Therapeutics, Inc.$61K
- Cook Research Incorporated$38K
- plus $3K from 1 others
What the payments were for
- Speaking & faculty fees$7,58060%
- Travel & lodging$7716%
- Food & beverage$8567%
- Education$3,50028%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Exelixis Inc. | 10 | $4,927 |
| Telix Pharmaceuticals | 3 | $4,473 |
| Pfizer | 4 | $2,820 |
| Cook Medical LLC | 3 | $251 |
| Boston Scientific | 1 | $124 |
| Baxter Healthcare | 1 | $111 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,707 in reported general payments places this provider in the 80th percentile of 369 urology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tamsulosin Hcl | 19 | $171 |
| Tramadol Hcl | 16 | $28 |
Paid to pharmacies, not to this prescriber.
Other urology in Atlanta
- Tariq HakkyAtlanta$140K
- James BennettAtlanta$93K
- Anthony BarnesAtlanta$89K
- Matthew SandAtlanta$77K
- Brendan BrowneAtlanta$53K
- Rajesh LaunganiAtlanta$33K
- Vikram NarayanAtlanta$29K
- Gregory MitchellAtlanta$15K
- Charles LorentzAtlanta$14K
- Vahan KassabianRoswell$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.